Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Resmetirom, which was also approved in August 2025 by the European Medicines Agency (EMA), is indicated for the treatment of adults with noncirrhotic MASH with moderate to advanced fibrosis and has been administered to over 23 000 patients in the USA ( On August 15th, 2025, the FDA granted an accelerated and conditional approval of the subcutaneous glucagonlike peptide (GLP1) receptor agonist (GLP1RA) semaglutide 2.4 mg/week for the treatment of MASH with moderate to advanced fibrosis (Stage F2F3) [7]
TB-500 (Thymosin Beta-4 fragment) increases actin-binding activity via T4-G-actin interaction , improving cell migration, tissue re-epithelialization, and anti-inflammatory cytokine modulation
It reaches therapeutic concentrations more efficiently than oral administration and allows localised injection near the injury site when appropriate
387:679-690 [PubMed: 26608256] 337
Curr Opin Rheumatol (2020) 32(1):719
Collectively, lipidic, polymeric, inorganic, and biomimetic systems now provide a modular toolkit for GLP-1 analogue delivery
US$ 29.51
US$ 26.36
US$ 22.55
US$ 23.45
US$ 25.95
US$ 20.78
US$ 25.62
